Bet Bromodomain Inhibitor manufacturers
|
| | Bet Bromodomain Inhibitor Basic information |
| Product Name: | Bet Bromodomain Inhibitor | | Synonyms: | (4S)-6-(4-Chlorophenyl)-1-methyl-4H-isoxazolo[5,4-d][2]benzazepine-4-acetamide;CPI0160;2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetaMide;2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide;4H-Isoxazolo[5,4-d][2]benzazepine-4-acetamide, 6-(4-chlorophenyl)-1-methyl-, (4S)-;CPI-0610;Pelabresib;0610 | | CAS: | 1380087-89-7 | | MF: | C20H16ClN3O2 | | MW: | 365.81 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1380087-89-7.mol |  |
| | Bet Bromodomain Inhibitor Chemical Properties |
| Boiling point | 622.8±55.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (273.37 mM; Need ultrasonic) | | form | Powder | | pka | 16.07±0.40(Predicted) | | color | White to off-white |
| | Bet Bromodomain Inhibitor Usage And Synthesis |
| Uses | BET Bromodomain Inhibitor has be shown to inhibit myeloma cell proliferation in clinically relevant models. |
| | Bet Bromodomain Inhibitor Preparation Products And Raw materials |
|